However, the propensity of immune tolerance in prostate cancer cannot be simply explained by the previous findings that the AR influences innate and adaptive immune systems by systematically suppressing neutrophil function and T and B cell development, as demonstrated in mice, and that AR activity in T cells limits ICI efficacy in patients with metastatic CRPC (9, 11). This evidence concerns the gene AR and prostate cancer.